was 4.7 years. Clinical, treatment, and dosimetric parameters evaluated for biochemical progression-free survival included primary Gleason grade; clinical T stage; pretreatment PSA level; risk group; percent positive biopsy results; perineural invasion; patient age; isotope; supplemental external-beam radiation therapy; prostate volume; brachytherapy planning volume; percent of the target volume receiving 100%, 150%, and 200% of the prescribed dose (V100/150/200); minimum percent of the prescribed dose covering 90% of the target volume (D90); tobacco consumption; hypertension; and diabetes.
R R E E S S U U L L T T S S
For the entire cohort, the actuarial 8-year biochemical progression-free survival rate was 94.5% and 94.8% using a PSA cutpoint ≤ 0.4 ng/mL after nadir and the ASTRO consensus definition, respectively. For biochemically diseasefree patients, the median posttreatment PSA level was < 0.1 ng/mL. When the group was stratified by the dominant histologic pattern, no statistical difference in outcome was noted for any of the evaluated parameters. In forward conditional Cox regression analysis, pretreatment PSA level and percent positive biopsy results were statistically significant predictors of biochemical outcome. Although the perception exists that biochemical outcome in patients with a Gleason score of 7 with dominant pattern 4 histology is inferior to that of patients with a Gleason score of 7 with a primary Gleason grade of 3, conflicting conclusions have been reported for radical prostatectomy and brachytherapy. In this study, we evaluate the effect of the dominant histologic pattern in Gleason score 7 prostate cancer on biochemical progression-free survival after brachytherapy.
M M A A T T E E R R I I A A L L S S A A N N D D M M E E T T H H O O D D S S
Between April 1995 and October 2001, 273 consecutive patients underwent permanent interstitial brachytherapy without androgen deprivation therapy for clinical T1c-T3a NxM0 (2002 American Joint Committee on Cancer) prostate cancer. No patient underwent seminal vesicle biopsy or pathological lymph node staging. All patients underwent brachytherapy more than 3 years before analysis. Biochemical progression-free survival was defined by a prostatespecific antigen (PSA) cutpoint ≤ 0.4 ng/mL after nadir or by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition. The median follow-up 234 tion of Physicists in Medicine Task Group No. 43 (TG-43). 18 Of The brachytherapy target volume consisted of a 3to 8-mm enlargement of the prostate gland on each ultrasound slice with a resultant planning volume approximately 1.75 times the ultrasound-determined volume. 19 The minimum peripheral dose (mPD) was prescribed to the planning target volume with margin. For monotherapeutic approaches, the mPD was 125 Gy NIST-99 for Pd 103 and 145 Gy TG-43 for I 125. Brachytherapy boost doses were 90 Gy mPD NIST-99 for Pd 103 and 110 Gy TG-43 mPD for I 125. The brachytherapy procedure was performed with preloaded 18-gauge needles using transverse and sagittal ultrasonography with fluoroscopy. At the time of implantation, the prostate gland, periprostatic region, and base of seminal vesicles received the implants. On average, 35%-40% of the seeds were placed in periprostatic locations. 20, 21 Patients were monitored by physical examination, including digital rectal examination, and PSA determinations at 3-to 6-month intervals. The endpoint of the analysis was biochemical disease-free survival defined by either a PSA level ≤ 0.4 ng/mL after a nadir or the ASTRO consensus definition. [14] [15] [16] No patient underwent routine postimplantation prostate biopsy.
Clinical, treatment, and dosimetric parameters evaluated for biochemical progression-free survival included primary Gleason grade; clinical T stage; pretreatment PSA level; risk group; percent positive biopsy result; perineural invasion; patient age; isotope; supplemental XRT; prostate volume; brachytherapy planning volume; percent of the target volume receiving 100%, 150%, and 200% of the prescribed dose (V100/150/200); minimum percent of Gleason score remains one of the most important predictors of the biologic aggressiveness of prostate cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In general, when the population is controlled for clinical stage and pretreatment prostatespecific antigen (PSA) level, patients with a Gleason score of 7 with primary pattern 4 histology possess greater rates of extracapsular extension without significant difference in seminal vesicle or pelvic lymph node involvement. 9 Although the perception exists that biochemical outcome in patients with a Gleason score of 7 with dominant pattern 4 histology is inferior to that of patients with a Gleason score of 7 with a dominant pattern 3, conflicting conclusions have accumulated after radical prostatectomy 1-3,6,7,11 and brachytherapy. 8, 12 In contrast, the two external-beam radiation therapy (XRT) series that evaluated the impact of primary grade in Gleason score 7 prostate cancer substantiated corroborated the adverse biochemical consequences of Gleason 4 + 3 histology. 10, 13 Previously, we reported the absence of a significant difference in biochemical progression after permanent prostate brachytherapy for hormone-naive patients with a Gleason score of 7 stratified by primary Gleason grade. 12 In this study, with the longer follow-up and the inclusion of additional patients, we report an 8-year biochemical progression-free survival using the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition and a PSA cutpoint ≤ 0.4 ng/mL after nadir. [14] [15] [16] 
At the Schiffler Cancer Center between April 1995 and October 2001, 273 consecutive patients with a Gleason score of 7 underwent interstitial brachytherapy using either Pd 103 or I 125 without androgen deprivation therapy for clinical T1c-T3a NxM0 (2002 American Joint Committee on Cancer) prostate cancer by a single brachytherapist (G.S.M.). Follow-up was calculated from the day of implantation. All patients underwent brachytherapy more than 3 years before analysis. Patients were clinically staged by medical history; physical examination, including digital rectal examination; and serum PSA level. Bone scans, computed tomography of the abdomen/pelvis, and enzymatic prostatic acid phosphatase level were obtained as clinically indicated. No patient underwent seminal vesicle biopsy or pathological lymph node staging.
All biopsy slides were reviewed by a single pathologist (E.A.) before the formulation of a treatment plan. 17 Calculation algorithms and seed parameters used in preplanning and postoperative dosimetry were those recommended by the American Associa-≤ 0.05 was considered significant. Statistical analysis was performed with SPSS version 12.0 software (SPSS, Inc., Chicago, IL). Table 1 summarizes the clinical, treatment, and dosimetric parameters of the 273 hormone-naive patients stratified by primary Gleason grade. The mean and median follow-up were 5.3± 2.1 years and 4.7 years, respectively. All patients underwent brachytherapy more than 3 years before analysis. The median patient age was 67.8 years (range, 44.6-80.1 years). Of the entire cohort, 238 patients (87.1%) presented with clinical stage T1c-T2b, and 220 patients (80.6%) presented with a pretreatment PSA level ≤ 10 ng/mL. The two cohorts were well-matched in terms of clinical, treatment, and dosimetric parameters except for a statistically significant, but probably clinically irrelevant, difference in percent positive biopsy results (50.4% vs 41.9% for Gleason 4 + 3 versus 3 + 4, P = 0.007).
the prescribed dose covering 90% of the target volume (D90); tobacco consumption; hypertension; and diabetes.
Hormone-naive patients with a Gleason score of 7 were grouped as 3 + 4 or 4 + 3. Clinical and treatment variables that were continuous were compared between the two groups with the use of an independent t test. Categorical variables were compared using a chi-square analysis. Gleason score 7 groups were also stratified by categorical variables and then compared across the two Gleason score 7 groups using Kaplan-Meier actuarial, 8-year, biochemical, progression-free survival analysis. The difference between failure rates using the two different definitions was analyzed by graphically placing the Kaplan-Meier curves of both onto the same figure; however, because both curves were developed from the same group of patients, no comparative analysis was undertaken. A forward conditional Cox regression analysis was used to determine whether any of the clinical or treatment variables predicted for failure. For all tests, a P value years (P = 0.280). For the 53 patients with a pretreatment PSA levels > 10 ng/mL, 77.8% and 84.6% of patients with primary Gleason pattern 3 and 4 histology, respectively, remained free of biochemical progression ( Fig. 5 , P = 0.498). Table 2 summarizes biochemical progression-free survival stratified by primary Gleason grade for multiple clinical, pathological, and treatment variables. Patient age, pretreatment PSA level, percent positive biopsy results, perineural invasion, risk group, supplemental XRT, or isotope did not predict for biochemical difference between patients with Gleason score 3 + 4 and those with score 4 + 3.
In univariate analysis, pretreatment PSA level, percent positive biopsy results, and larger prostate volume predicted for biochemical success (Table 3) . However, in forward conditional Cox regression analysis, only pretreatment PSA level (P < 0.001) and Figure 1 illustrates Kaplan-Meier biochemical progression-free survival for the 273 hormone-naive patients. At 8 years, a PSA cutpoint ≤ 0.4 ng/mL after nadir and the ASTRO consensus definition resulted in freedom from biochemical progression rates of 94.5% and 94.8%, respectively. For both cohorts, the median posttreatment PSA level in biochemically disease-free patients was < 0.1 ng/mL (Table 1) . Figures 2 and 3 graphically display biochemical progression-free survival stratified by the dominant histologic grade. Both progression-free definitions resulted in nearly identical rates of biochemical success, and neither definition demonstrated a statistically significant difference in outcome when the data were stratified by primary grade. Figure 4 illustrates biochemical outcome for patients with a pretreatment PSA level ≤ 10 ng/mL stratified by the dominant histologic pattern. In patients with dominant pattern 3 and 4 histology, 99.3% and 96.2% of patients, respectively, remained free of biochemical progression at 8 (myocardial infarction in five, cerebrovascular accident in one, colon cancer in one, lung cancer in one, gastrointestinal bleeding in one, and complications of Alzheimer' s disease in one).
D D I I S S C C U U S S S S I I O O N N
The histologic assessment of Gleason score represents an important prognostic indicator of the biologic aggressiveness of prostate cancer, with higher Gleason scores negatively influencing biochemical outcome. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 22 Although the perception exists that patients with a Gleason score of 7 can be stratified into prognostic categories by the dominant histologic grade, conflicting results have been published in both the radical prostatectomy 1-3,6,7,11 and the brachytherapy 8, 12 literature.
In patients who with a Gleason score of 7 who have undergone radical prostatectomy without seminal vesicle or pelvic lymph node involvement, Chan and colleagues 6 reported 10-year biochemical diseasefree survival rates of 56% and 37% for Gleason 3 + 4 versus 4 + 3, respectively (P < 0.0001). Although the percent positive biopsy results (P = 0.007) were statistically significant predictors of biochemical outcome. To date, one patient has died of metastatic prostate cancer, whereas 10 have died of other causes Gleason score 3 + 4 versus 4 + 3. Consistent with this finding, investigators at Fox Chase reported a nonstatistical trend for improved biochemical outcome for Gleason score 3 + 4 versus 4 + 3 (74% vs 65%, P = 0.26). 13 However, a statistically significant difference in biochemical outcome for patients with a Gleason score of 7 was noted when the data were stratified by XRT dose, with a 5-year freedom from biochemical progression of 76%, versus 54% in patients receiving doses < 76 Gy versus ≥ 76 Gy (P = 0.0019). 13 In particular, a 100% 5-year rate of biochemical freedom from progression was reported for patients with a pretreatment PSA level < 10 ng/mL who received the higher XRT doses. 13 In the current study, the two Gleason score 7 cohorts were well matched in terms of clinical, treatment, and dosimetric parameters, with no discernable difference in 8-year biochemical progression-free survival for patients with a Gleason score of 3 + 4 versus those with a score of 4 + 3 (Fig. 1) . Because of the radiation dose-intensification effect of brachytherapy, the median posttreatment PSA level in patients free of biochemical progression was < 0.1 ng/mL. Because of the ablative PSA response, the biochemical progression-free survival curves were nearly equivalent using either a PSA cutpoint ≤ 0.4 ng/mL after nadir or the ASTRO consensus definition.
Kaplan-Meier Progression-Free Survival (%) for Various Demographic, Clinical, and Treatment Parameters
Although some patients with a Gleason score of 7 may have subclinical distant metastatic disease at diagnosis, multiple studies seriously question this presumption for the vast majority of patients. An evaluation of Radiation Therapy Oncology Group trials demonstrated an improvement in overall 5-year survival for patients with higher Gleason scores who received higher XRT doses. 24 In addition, improvements in 5-year cause-specific survival were reported for hormone-naive patients undergoing dose-escalated high-dose-rate brachytherapy. 25 For patients with a Gleason score of 8-10 who underwent radical prostatectomy, Do and colleagues 26 reported a 5-year biochemical progression-free survival of 20% for radical prostatectomy alone, but 65% for those who underwent radical prostatectomy and postoperative XRT. These findings do not support the hypothesis that most patients with higher Gleason scores have subclinical distant metastases at diagnosis, but rather support the contention that an aggressive locoregional approach can result in a high probability of biochemical success.
Radical prostatectomy series have reported that 99% of all extracapsular extension is limited to within 5 mm of the prostate capsule. 27, 28 Patients at significant risk for extracapsular extension, but at low risk for pelvic lymph node involvement/distant metastases, remain potentially curable via an aggressive lo-risk of extracapsular extension was substantially greater in patients with a predominant Gleason grade 4 pattern (52.7% vs 38.2%, P = 0.008), the incidence of positive surgical margins was comparable (10.9% vs 10.7%). The authors concluded that Gleason 4 + 3 resulted in a greater biochemical progression rate independent of stage and margin status, insinuating that failure was a result of subclinical distant metastatic disease. However, the molecular assessment of surgical margins has questioned the accuracy of conventional hematoxylin and eosin pathological evaluation. 23 As such, subclinical locoregional failure remains a possible source of biochemical progression.
In contrast, in an evaluation of 823 radical prostatectomy specimens, Herman and colleagues 1 identified primary histologic grade in patients with a Gleason score of 7 as a significant predictor of disease progression in univariate, but not multivariate, analysis (P = 0.76). The authors hypothesized that the "single arbitrary cutpoint of 51% to establish primary Gleason grade is either too high or too low and may need to be adjusted." 1 Consistent with that study, Groll and colleagues 11 reported that when patients with biopsy Gleason score of 7 were stratified by primary pattern 3 or 4, the incidences of extracapsular extension, positive surgical margins, and seminal vesicle involvement were not significantly different, and the authors questioned the utility of even assigning a primary grade among Gleason score 7 patients.
After XRT, two studies evaluated the impact of the dominant histology pattern in patients with a Gleason score of 7. 10,13 D'Amico and colleagues 10 identified a significant cutpoint in biochemical outcome between coregional approach. A review of the Partin tables illustrates that the vast majority of our patients possessed a significant risk of extracapsular extension, but a low incidence of seminal vesicle and/or pelvic lymph node involvement. 9 We hypothesize that our favorable outcomes are a result of dose escalation far exceeding XRT and the ability to irradiate the periprostatic tissue with generous treatment margins. 21, 29 With the use of carefully selected periprostatic seeds, day 0 computed tomography-based dosimetry has demonstrated extracapsular treatment margins of 6.5 and 9.6 mm at the 100% and 75% isodose lines, respectively. 21 
Forward Conditional Cox Regression Analysis

C C O O N N C C L L U U S S I I O O N N
In hormone-naive patients with a Gleason score of 7, prostate brachytherapy with generous periprostatic margins obtained by either the placement of periprostatic seeds and/or the use of supplemental XRT results in a high probability of 8-year biochemical progression-free survival and is independent of Gleason 3 + 4 versus 4 + 3 histology.
